Role of Endothelial Biomarkers in Patients With Coronary Artery Disease
NCT ID: NCT03146208
Last Updated: 2017-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
54 participants
OBSERVATIONAL
2017-07-01
2019-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Telomeres are short in circulating leucocytes in patients with coronary artery disease but the precise mechanism is not well-known (3).
Telomere and telomerase are affected by cytomegalovirus (CMV) infection due to its effect on increasing the number of highly differentiated T cells that are characterized by shorter telomere length (TL) and lowered telomerase activity (TA). Both genetic and environmental factors have been connected with individual distinction in TL.Cardiovascular risk factors such as smoking, diabetes mellitus, hypertension, obesity, and stress have been considered to upsurge inflammation, oxidative stress, therefore accelerating TL shortening (1,2)
It has also been observed that telomere loss in type 2 diabetic patients contributes to oxidative stress and endoplasmic reticulum stress while telomere shortening has also been proposed that it can serve as an independent risk factor of T2DM and it can measure disease progression(4).
Moreover, telomeric length in peripheral blood mononuclear cells (PBMCs) is associated with the duration of disease and good glycemic control seems to be protective for telomeric loss (5).
Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor (TGF)-β superfamily. GDF-15, recently identified as one of the new cardioprotective cytokines. It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk(6).
Dipeptidyl peptidase inhibitors (DPP4 -I) are called gliptins which increase the incretin levels and therefore prolong the post-prandial insulin action(7).
Diana et al reported that In type 2 diabetic patients, leukocyte telomere was significantly shorter than control groups and was significantly elongated after intervention by sitagliptin(8).
The common feature of all risk factors of CAD and T2DM imbalance between pro- and anti-oxidative factors in the organism with an increased production of reactive oxygen species (ROS).Nuclear factor erythroid-derived factor 2-related factor 2(Nrf2) is a family of transcription factors which plays an important role in protection against CVD and DM by regulating antioxidant enzymes in cells after ROS exposure (9).
In our study, we will propose a model, which would provide the basis to establish a marker for chronic reactivation of CMV and shed more light into the pathophysiology of CMV infection in patients with CAD in relation to GDF-15 and NrF2 and their implications on disease progression. Ultimately, this would then enable us to identify patients at risk and develop novel strategies for future treatment and prevention of heart diseases in our country. In light of our project research, the question arises whether telomere length could represent a marker of chronic CMV reactivation and uncertainty their length will be modified by the effect of DPP-4 or not?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation of Biomarkers With the Presence and Severity of Coronary Artery Disease
NCT05015270
Diagnostic and Prognostic Value of Angiography-derived IMR
NCT04825028
Could Non-invasive Biochemical, Image or Physiological Index Predict Significant Coronary Arterial Stenosis in Symptomatic Adults?
NCT01645228
Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases
NCT06690684
Association Between Peri-procedural Myocardial Injury and Quantitative Blood Flow Ratio
NCT07110298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. We will be able to answer whether there is a link between the seropositive CMV, telomere length, and CAD.
3. We will correlate the seropositive CMV with telomere length, GDF-15 \& NRF2.
4. We will detect the origin of our biomarkers by human umbilical vein endothelial cells(HUVECS).
5. We will measure the effect of DPP4-I (on TL \& GDF-15 on cardiac cell line).
6. We are looking to establish a new potential risk marker from our study, (GDF-15 \& NRF2) which could be tested in a larger cohort of patients. This would then enable us to identify CMV-seropositive patients at risk and develop novel strategies for future treatment and prevention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coronary artery disease patients with type 2 DM
Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
No interventions assigned to this group
Coronary artery disease patients without type 2 DM
The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
No interventions assigned to this group
Healthy control group
we will include 54 age-matched patients with normal angiogram
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. All patients with risk factors such as hypertension, hyperlipidemia and smokers.
Exclusion Criteria
2. Cancers.
3. Strock.
4. Acute and chronic inflammation and Autoimmune diseases were excluded from the study.
25 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Naglaa Kamal Idriss
Doctor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Qi Nan W, Ling Z, Bing C. The influence of the telomere-telomerase system on diabetes mellitus and its vascular complications. Expert Opin Ther Targets. 2015 Jun;19(6):849-64. doi: 10.1517/14728222.2015.1016500. Epub 2015 Feb 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17200057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.